Drugs / Allicor
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01734707 | Jan 2004 → Jan 2005 | atherosclerosis | Institute for Atherosclerosis Research, Russia | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05813171 | Apr 2023 → Apr 2024 | atherosclerosis, peripheral arterial disease | Institute for Atherosclerosis Research, Russia | Unknown | No outcome recorded |
| Phase 4 | NCT05803759 | Apr 2023 → Mar 2024 | coronary atherosclerosis, myocardial ischemia | Institute for Atherosclerosis Research, Russia | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allicor | “Participants will take Allicor capsules in addition to standard treatment for a year.” NCT05813171 ↗2“Dietary Supplement: Allicor 150 mg capsule by mouth two times a day” NCT05803759 ↗ “time-released garlic-based drug Allicor” NCT01734707 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Since Allicor is the remedy of natural origin” PMID 20958974 ↗ Oct 2010 |
| Route | Oral | “Allicor 150 mg tablet by mouth two times a day” NCT01734707 ↗ |